Polyclonal Antibody to RANKL (CD254)

Background
CD254 is a member of the tumor necrosis factor family. TRANCE (TNF-related activation-induced cytokine receptor) or RANKL {receptor activator of NF-kB (RANK) ligand} has been implicated in interactions between T cells and dendritic cells (1-2). CD254 binds to RANK on DCs, upregulates the expression of anti-apoptotic protein BcL-XL suggesting a role in DC survival (2). CD254 is also important in Tcell and Bcell maturation (3). As OPGL/ODF (Osteoprotegerin Ligand/Osteoclast differentiation factor), CD254 can both activate mature osteoclasts and mediate osteoclastogenesis (4,5). CD254 deficient mice show severe osteoporesis and complete absence of osteoclasts as a result of lack of osteogenesis (3).  Mouse CD254 is a 316 amino acid protein.

Antigen
Recombinant mouse CD254 containing amino acid residues 157-316 was used as immunogen for this antibody.

Application Notes
Additional RANKL (CD254) antibodies and products can be found here

Reference
1. Hsu, H., Lacey, D.L., Dunstan, C.R., Solovyev, I., et al. Proc. Natl. Acad. Sci. USA 96: 3540-3545 (1999).
2. Lacey, D.L. Timms, E,. Tan, H.L., Kelly, M.J. , et al. Cell 93: 165-176 (1998).
3. Kong, Y-Y., Yoshida, H., Sarosi, I., Tan, H-L., et al. Nature 397: 315-323 (1999).
4. Wong, B.R., Josien, R., Lee, S.W., Sauter, B., Li, H-L., Steinman, R.M., and Choi, Y. J. Exp. Med. 186: 2075-2080.
5. Anderson, D.M, Maraskovsky, E., Billingsley, W.L., Dougall, W.C., Tometsko, M.E., Roux, E.R., Teepe, M.C., DuBose, R.F., Cosman, D., and Gaibert, L. Nature 390: 175-179 (1997).
6. Atish Mukherjee, Selma M. Soyal, Jie Li, Yan Ying, Bin He, Francesco J. DeMayo, John P. Lydon.  Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression.  FASEB J. 2010 November; 24(11): 4408–4419.
7. Lisa J. Robinson, Beatrice B. Yaroslavskiy, Reed D. Griswold, Eva V. Zadorozny, Lida Guo, Irina L. Tourkova, Harry C. Blair.  Estrogen Inhibits RANKL-stimulated Osteoclastic Differentiation of Human Monocytes through Estrogen and RANKL-regulated Interaction of Estrogen Receptor-α with BCAR1 and Traf6.  Published in final edited form as: Exp Cell Res. 2009 April 15; 315(7): 1287–1301. Published online 2009 January 30.
8. Ann E. Kearns, Sundeep Khosla, Paul J. Kostenuik.  Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease.  Endocr Rev. 2008 April; 29(2): 155–192. Published online 2007 December 5.